×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
A Collaborative Cross-Company Pediatric Platform Trial in Pediatric Crohn’s Disease Using an Innovative Bayesian Analysis
Session Chair(s)
Robert "Skip" Nelson, MD, PhD
Senior Director, Pediatric Drug Development (CHILD)
Johnson & Johnson, United States
Innovative approaches to pediatric drug development are needed to reduce the delay between adult and pediatric marketing approval. This session presents a cross-company pediatric platform trial in Crohn's disease using a Bayesian analysis.
Learning Objective : Identify some of the recruitment challenges in pediatric drug development; Identify the role of platform trials in addressing these challenges; Discuss the clinical, scientific, regulatory, and operational challenges in designing and implementing a cross-company pediatric platform trial.
Speaker(s)
Industry Update
Laurie Conklin, DrMed, MD
Janssen, United States
Director, Pediatric Immunology
Industry Update
Wendy Komocsar
Eli Lilly and Company , United States
Research Advisor, Immunology
Industry Update
Forrest Williamson, PhD
Eli Lilly and Company, United States
Director of Pediatrics, Statistical Innovation Center
Have an account?